drugset / Trial / NCT07490613
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
NaSequentialOpen-labelTreatment
Summary
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
Timeline
- Start
- 2026-06-02
- Primary completion
- 2028-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-3836 | Unknown | — | — |